Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Entrectinib Formulations F1 and F06 Under Fed Conditions
NCT03796260Phase 1Completed
- Sponsor
- Genentech
- Start
- Jan 2019
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of entrectinib in NTRK fusion-positive solid tumor and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Genentech. Primary endpoints: Area Under the Concentration-Time Curve Extrapolated to Infinity, Area Under the Concentration-Time Curve and 1 more. Started Jan 2019; status: completed.
02
Drugs
entrectinib
03
Conditions
NTRK fusion-positive solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03796260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03796260.